Zavante Therapeutics Secures $45,000,000 Series A Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=592c6422-b104-4006-8b6a-a4cf39571157 - Date
3/30/2016 - Company Name
Zavante Therapeutics - Mailing Address
12670 High Bluff Dr. San Diego, CA 92130 USA - Company Description
We are passionately committed to our mission to improve patients’ lives by identifying, developing and commercializing novel therapeutics addressing significant unmet medical needs in the hospital setting. - Website
http://www.zavante.com - Transaction Type
Venture Equity - Transaction Amount
$45,000,000 - Transaction Round
Series A - Proceeds Purposes
The company has closed a $45 million Series A financing, consisting of $35 million from new investors and $10 million from the conversion of outstanding convertible notes. Proceeds from the financing will be used for the development of the Company’s lead product candidate, ZTI-01 (fosfomycin for injection), an injectable antibiotic with a differentiated mechanism of action designed for use in the hospital setting. In the second quarter of 2016, Zavante plans to initiate the ZEUS Study, a single pivotal clinical trial for ZTI-01, a first-in-class broad spectrum IV antibiotic under development to treat multidrug resistant (MDR) pathogens. - M&A Terms
- Venture Investor
Frazier Healthcare Partners - Venture Investor
Longitude Capital Management - Venture Investor
Aisling Capital
